HomeCompareMSPAF vs MRK

MSPAF vs MRK: Dividend Comparison 2026

MSPAF yields 33.78% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSPAF wins by $107.5K in total portfolio value
10 years
MSPAF
MSPAF
● Live price
33.78%
Share price
$5.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.3K
Annual income
$24,076.27
Full MSPAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — MSPAF vs MRK

📍 MSPAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSPAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSPAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSPAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSPAF
Annual income on $10K today (after 15% tax)
$2,871.62/yr
After 10yr DRIP, annual income (after tax)
$20,464.83/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MSPAF beats the other by $12,136.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSPAF + MRK for your $10,000?

MSPAF: 50%MRK: 50%
100% MRK50/50100% MSPAF
Portfolio after 10yr
$110.5K
Annual income
$16,937.20/yr
Blended yield
15.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MSPAF
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSPAF buys
0
MRK buys
0
No recent congressional trades found for MSPAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSPAFMRK
Forward yield33.78%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$164.3K$56.8K
Annual income after 10y$24,076.27$9,798.13
Total dividends collected$117.1K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSPAF vs MRK ($10,000, DRIP)

YearMSPAF PortfolioMSPAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,078$3,378.38$11,206$366.19+$2.9KMSPAF
2$19,509$4,445.06$12,650$502.35+$6.9KMSPAF
3$26,631$5,756.70$14,407$694.19+$12.2KMSPAF
4$35,840$7,344.27$16,585$967.82+$19.3KMSPAF
5$47,586$9,237.14$19,342$1,363.89+$28.2KMSPAF
6$62,379$11,462.13$22,913$1,947.19+$39.5KMSPAF
7$80,788$14,042.43$27,662$2,823.89+$53.1KMSPAF
8$103,440$16,996.79$34,159$4,173.35+$69.3KMSPAF
9$131,019$20,338.78$43,337$6,308.80+$87.7KMSPAF
10$164,267$24,076.27$56,776$9,798.13+$107.5KMSPAF

MSPAF vs MRK: Complete Analysis 2026

MSPAFStock

Growens S.p.A., together with its subsidiaries, engages in the cloud marketing technology business in Italy, other European countries, the Americas, and Asia. It operates through E-mail Marketing, Mobile Marketing/Messaging, and Marketing Automation Segments. The company is involved in the development and sale of technologies for the mass sending of e-mails and mobile messaging through the SMS channel for marketing and transaction purposes. It also provides e-mail and newsletter editing tools; marketing technology solutions; and professional consulting services. In addition, the company offers MailUp, a platform that offers data presentation tools, including statistics for engagement that presents statistical data to help users enhance the effectiveness of their campaigns through e-mail and then to take corrective actions to enhance the performance of future campaigns, as well as the multi-list dashboard feature, which is a summary tool to have an immediate overview of the progress of campaigns. Further, it provides BEE, a drag-and-drop editor for e-mails and landing pages; Acumbamail, a Spanish e-mail marketing platform, which allows the creation, sending, and management of multi-channel marketing campaign; and Datatrics platform, which allows the marketing teams to build experiences based on data managed by artificial intelligence. The company was formerly known as Mailup S.p.A. and changed its name to Growens S.p.A. in April 2021. Growens S.p.A. was founded in 2002 and is headquartered in Milan, Italy.

Full MSPAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MSPAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSPAF vs SCHDMSPAF vs JEPIMSPAF vs OMSPAF vs KOMSPAF vs MAINMSPAF vs JNJMSPAF vs ABBVMSPAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.